The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

被引：99

作者：

Chiarle, Roberto ^{[1
,2
]}

Martinengo, Cinzia ^{[1
]}

Mastini, Cristina ^{[1
,3
]}

Ambrogio, Chiara ^{[1
,2
]}

D'Escamard, Valentina ^{[4
,5
]}

Forni, Guido ^{[3
]}

Inghirami, Giorgio ^{[1
,2
,4
,5
]}

机构：

[1] Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy

[2] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy

[3] Univ Turin, Dept Clin & Biol Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy

[4] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA

[5] NYU, Sch Med, New York Canc Ctr, New York, NY 10016 USA

来源：

NATURE MEDICINE | 2008年 / 14卷 / 06期

关键词：

D O I：

10.1038/nm1769

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

An ideal vaccination strategy against tumors relies on specific antigens that are required for tumor maintenance(1). For lymphoma, vaccination with subject-specific immunoglobulin idiotypes has had the most promising results(2,3). Here we show that DNA vaccination with plasmids encoding portions of the cytoplasmic domain of anaplastic lymphoma kinase (ALK), which has been translocated in different fusion proteins necessary for the growth of anaplastic large cell lymphoma (ALCL)(4), protects mice from local and systemic lymphoma growth. The protection is potent and long lasting and elicits ALK-specific interferon-c responses and CD8(+) T cell-mediated cytotoxicity. A combination of chemotherapy and vaccination significantly enhanced the survival of mice challenged with ALK(+) lymphomas. These findings indicate that ALK represents an ideal tumor antigen for vaccination-based therapies of ALCL and possibly other ALK(+) human tumors(4-7).

引用

页码：676 / 680

页数：5

共 30 条

[1]

CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma [J].